Dexmedetomidine and Nalbuphine as Analgesic Adjuvants to Bupivacaine in Superficial Cervical Block.
Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age21-60
SponsorKasr El Aini Hospital
About this trial
Anterior cervical discectomy and fusion (ACDF) nowadays is considered a common procedure.postoperative pain can hinder recovery and prolong hospital stay. The superficial cervical plexus block (SCPB) is a safe and simple technique that had been found to allow good pain relief in neck surgeries. The main drawback of SCPB was short duration, so adjuvants as dexmedetomidine and opioids has been used to increase analgesic duration and decrease the use of opioids.
The current study will compare the efficacy of dexmedetomidine and nalbuphine as adjuvants to bupivacaine in SCPB in anterior cervical fusion surgeries.
Eligibility criteria
Qualifiers
Physical status ASA I and ASA ll.
Both males and females
Age 21- 60 years.
Patients undergoing elective anterior cervical discectomy and fusion for 1 or 2 levels.
Disqualifiers
Patient refusal.
Patients undergoing anterior cervical vertebrectomy and reconstruction.
Patients with a history of allergy to local anesthetics or any used drugs in study.
Infection at the site of the block.
Trial design
Treatments tested in this trial
- Dexmedetomidine in superficial cervical plexus block
- Nalbuphine in superficial cervical plexus block
Treatment groups
30 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov